IP Verse

Immunotherapeutic Molecules And Uses - EP2819701

The patent EP2819701 was granted to The University OF Birmingham on Jun 2, 2021. The application was originally filed on Feb 28, 2013 under application number EP13719592A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2819701

THE UNIVERSITY OF BIRMINGHAM
Application Number
EP13719592A
Filing Date
Feb 28, 2013
Status
Patent Maintained As Amended
Apr 30, 2021
Grant Date
Jun 2, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

F HOFFMANN LA ROCHEApr 23, 2019BOULT WADE TENNANTWITHDRAWN

Patent Citations (10) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONWO9824478
EXAMINATIONWO2005083431
EXAMINATIONWO2009024771
EXAMINATIONWO9634892
INTERNATIONAL-SEARCH-REPORTWO2010081173
OPPOSITIONUS2010189727
OPPOSITIONUS2011229476
OPPOSITIONWO2010081173
OPPOSITIONWO9634892
OPPOSITIONWO9954440

Non-Patent Literature (NPL) Citations (40) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- BRUHL, J IMMUNOL, (2001), vol. 166, pages 2420 - 6
DESCRIPTION- GIOVANNONI ET AL., "Isolation of anti-angiogenesis antibodies from a large combinatorial repertoire by colony filter screening", NUCLEIC ACIDS RES., (2001), vol. 29, page E27
DESCRIPTION- JULIAN ET AL., ANAL. BIOCHEM., (1983), vol. 132, page 68
DESCRIPTION- KOHLER; MILSTEIN, "Continuous cultures of fused cells secreting antibody of predefined specificity", NATURE, (1975), vol. 256, pages 495 - 497, XP002024548
DESCRIPTION- KUFER, CANC IMMUNOL IMMUNOTHER, (1997), vol. 45, pages 193 - 7
DESCRIPTION- LOFTIER, BLOOD, (2000), vol. 95, pages 2098 - 103
DESCRIPTION- MACK, J IMMUNOL, (1997), vol. 158, pages 3965 - 70
DESCRIPTION- MACK, PNAS, (1995), vol. 92, pages 7021 - 5
DESCRIPTION- MEZIERE ET AL., J. IMMUNOL., (1997), vol. 159, pages 3230 - 3237
DESCRIPTION- O'SULLIVAN ET AL., ANAL. BIOCHEM., (1979), vol. 100, pages 100 - 108
DESCRIPTION- PLANT, ANALYT BIOCHEM, (1995), vol. 226, no. 2, pages 342 - 348
DESCRIPTION- RAWLINGS N.D.; MORTON F.R.; KOK, C.Y.; KONG, J.; BARRETT A.J., "MEROPS: the peptidase database", NUCLEIC ACIDS RES., (2008), vol. 36, pages 320 - 325
DESCRIPTION- STAERZ, NATURE, (1985), vol. 314, page 628
DESCRIPTION- CARTER, "Introduction to current and future protein therapeutics: a protein engineering perspective", EXP CELL RES., (2011), vol. 317, no. 9, doi:doi:10.1016/j.yexcr.2011.02.013, pages 1261 - 9, XP028205664
DESCRIPTION- SCHAFFITZEL ET AL., "Ribosome display: an in vitro method for selection and evolution of antibodies from libraries", J. IMMUNOL. METHODS, (1999), vol. 231, doi:doi:10.1016/S0022-1759(99)00149-0, pages 119 - 135, XP004186079
DESCRIPTION- CARTER, "Potent antibody therapeutics by design", NAT REV IMMUNOL., (2006), vol. 6, no. 5, doi:doi:10.1038/nri1837, pages 343 - 57, XP007901440
DESCRIPTION- WINTER ET AL., "Making antibodies by phage display technology", ANNU. REV. IMMUNOT., (1994), vol. 12, doi:doi:10.1146/annurev.iy.12.040194.002245, pages 433 - 455, XP000564245
INTERNATIONAL-SEARCH-REPORT- BAEUERLE PATRICK A ET AL, "BiTE: Teaching antibodies to engage T-cells for cancer therapy", CURRENT OPINION IN MOLECULAR THERAPEUTICS, THOMSON REUTERS (SCIETIFIC) LTD, (20090201), vol. 11, no. 1, ISSN 2040-3445, pages 22 - 30, XP009151509 [Y] 1-46 * the whole document *
INTERNATIONAL-SEARCH-REPORT- MOLHOJ ET AL, "CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis", MOLECULAR IMMUNOLOGY, PERGAMON, GB, (20061201), vol. 44, no. 8, doi:10.1016/J.MOLIMM.2006.09.032, ISSN 0161-5890, pages 1935 - 1943, XP005792730 [Y] 1-46 * Abstract. *
INTERNATIONAL-SEARCH-REPORT- R. LUTTERBUESE ET AL, "T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (20100713), vol. 107, no. 28, doi:10.1073/pnas.1000976107, ISSN 0027-8424, pages 12605 - 12610, XP055067703 [Y] 1-46 * Abstract; Discussion *
OPPOSITION- Anonymous, "Purified anti-human CD3-Antibody", BioLegend, (20130612), pages 1 - 2
OPPOSITION- Anonymous, "Purified anti-human CD3-Antibody", BioLegend, (20130612), pages 1 - 2, XP055595817
OPPOSITION- BRISCHWEIN et al., "Strictly target cell -dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class", J Immunother, (20070000), vol. 30, no. 8, doi:10.1097/CJI.0b013e318156750c, pages 798 - 807
OPPOSITION- DONALDSON et al., "Design and development of masked therapeutic antibodies to limit off-target effects", Cancer Biol Ther, (20090000), vol. 8, no. 22, doi:10.4161/cbt.8.22.9765, pages 2147 - 2152
OPPOSITION- LINK et al., "Anti- CD 3-based bispecific antibody designed for therapy of human B- cell malignancy can induce T- cell activation by antigen-dependent and antigen- independent mechanisms", Int. J. Cancer, (19980000), vol. 77, doi:10.1002/(SICI)1097-0215(19980717)77:2<251::AID-IJC14>3.0.CO;2-E, pages 251 - 256
OPPOSITION- LOFFLER et al., "A recombinant bispecific single-chain antibody , CD 19 x CD 3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes", Blood, (20000000), vol. 95, no. 6, pages 2098 - 2103
OPPOSITION- LOFFLER et al., "A recombinant bispecific single-chain antibody , CD 19 x CD 3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes", Blood, (20000000), vol. 95, no. 6, pages 2098 - 2103, XP002572419
OPPOSITION- LUM et al., "Preclinical studies comparing different bispecific antibodies for redirecting T cell cytotoxicity to extracellular antigens on prostate carcinomas", Anticancer Research, (20050000), vol. 25, pages 43 - 52
OPPOSITION- LUM et al., "Preclinical studies comparing different bispecific antibodies for redirecting T cell cytotoxicity to extracellular antigens on prostate carcinomas", Anticancer Research, (20050000), vol. 25, pages 43 - 52, XP008066875
OPPOSITION- Patrick A. Baeuerle and Carsten Reinhardt, "Bispecific T cell engaging antibodies for cancer therapy", Cancer Res., (20090000), vol. 69, no. 12, pages 4941 - 4944
OPPOSITION- THAKUR et al., "Cancer therapy with bispecific antibodies: Clinical experience", Curr Opin Mol Ther, (20100000), vol. 12, no. 3, pages 340 - 349
OPPOSITION- THAKUR et al., "Cancer therapy with bispecific antibodies: Clinical experience", Curr Opin Mol Ther, (20100000), vol. 12, no. 3, pages 340 - 349, XP009145639
OPPOSITION- THOMPSON et al., "Preclinical evaluation of light-activatable, bispecific anti-human CD 3 antibody conjugates as anti-ovarian cancer therapeutics", mAbs, (20090000), vol. 1, no. 4, doi:10.4161/mabs.1.4.9045, pages 348 - 356
OPPOSITION- WU et al., "Fab-based bispecific antibody formats with robust biophysical properties and biological activity", mAbs, (20150000), vol. 7, no. 3, doi:10.1080/19420862.2015.1022694, pages 470 - 482
OPPOSITION- LINK et al., "Anti- CD 3-based bispecific antibody designed for therapy of human B- cell malignancy can induce T- cell activation by antigen-dependent and antigen- independent mechanisms", Int. J. Cancer, (19980000), vol. 77, doi:10.1002/(SICI)1097-0215(19980717)77:2<251::AID-IJC14>3.0.CO;2-E, pages 251 - 256, XP055485128
OPPOSITION- WU et al., "Fab-based bispecific antibody formats with robust biophysical properties and biological activity", mAbs, (20150000), vol. 7, no. 3, doi:10.1080/19420862.2015.1022694, pages 470 - 482, XP009185560
OPPOSITION- BRISCHWEIN et al., "Strictly target cell -dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class", J Immunother, (20070000), vol. 30, no. 8, doi:10.1097/CJI.0b013e318156750c, pages 798 - 807, XP055276936
OPPOSITION- Patrick A. Baeuerle and Carsten Reinhardt, "Bispecific T cell engaging antibodies for cancer therapy", Cancer Res., (20090000), vol. 69, no. 12, pages 4941 - 4944, XP002665118
OPPOSITION- DONALDSON et al., "Design and development of masked therapeutic antibodies to limit off-target effects", Cancer Biol Ther, (20090000), vol. 8, no. 22, doi:10.4161/cbt.8.22.9765, pages 2147 - 2152, XP009135774
OPPOSITION- THOMPSON et al., "Preclinical evaluation of light-activatable, bispecific anti-human CD 3 antibody conjugates as anti-ovarian cancer therapeutics", mAbs, (20090000), vol. 1, no. 4, doi:10.4161/mabs.1.4.9045, pages 348 - 356, XP055148604

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents